Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-31 · accession 0001867096-25-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-03 | 2025-01-31 | XERS | Pieper Steven | See Remarks | F - Tax | $3.56 | -177.2K | 1.30M | -12% | -$630.8K |
| D | 2025-02-03 | 2025-01-31 | XERS | Pieper Steven | See Remarks | A - Grant | $0.00 | +185.0K | 1.42M | +15% | $0 |
| D | 2025-02-03 | 2025-01-31 | XERS | Pieper Steven | See Remarks | A - Grant | $0.00 | +300.0K | 300.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | F | D | 66,450 | $3.56 | 1,232,561 | D | — | — | (F1) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. |
| 2 | Common | Common Stock | 2025-01-31 | F | D | 110,750 | $3.56 | 1,299,011 | D | — | — | (F1) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. |
| 3 | Common | Common Stock | 2025-01-31 | A | A | 185,000 | $0.00 | 1,417,561 | D | — | — | (F2) These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. |
| 4 | Derivative | Stock Appreciation Right | 2025-01-31 | A | A | 300,000 | $0.00 | 300,000 | D | $3.56 · — to 2027-03-02 | 300,000 Common Stock | (F3) This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date. |